Addition of the monoclonal antibody stapokibart significantly improved nasal polyps and nasal congestion in adults with uncontrolled chronic rhinosinusitis with nasal polyps, based on new data from 179 individuals.

Biologics are now more commonly used as treatments for chronic rhinosinusitis with nasal polyps (CRSwNP), and monoclonal antibodies have emerged as significantly more effective than other biologics for these patients, wrote Shen Shen, MS, of Capital Medical University, Beijing, China, and colleagues.

In a study known as CROWNS-2 published in JAMA , the researchers randomly assigned 180 adults with CRSwNP to stapokibart (300 mg subcutaneously) or a placebo injection every 2 weeks for 24 weeks. All participants also received 100 μg of mometasone furoate per nostril once a da

See Full Page